AllSci News
K2 Therapeutics commits up to USD 980m on masked TCE platform from Antengene
China-based Antengene Corporation Limited (HKEX: 6996) has licensed its preclinical CDH6 × CD3 bispecific T cell engager ATG-106 to K2 Therapeutics, a...
Memento launches with USD 93m to challenge anti-VEGF monopoly in retinal disease
Boston-based Memento Medicines, Inc. has launched with a USD 93 million Series A financing round to advance MMT-205 (previously known as MT-103), a...
Syntax Bio raises USD 14.4m to scale CRISPR-programmed cell therapy for type 1 diabetes
Chicago-based Syntax Bio has closed an expanded Series A totaling USD 14.4 million, bringing total funding to more than USD 25 million, as the synthetic...
SOPHiA Genetics raises USD 57.5 million to expand AI genomics platform beyond oncology
Switzerland-based SOPHiA GENETICS (Nasdaq: SOPH), an AI-native healthcare technology company, announced the closing of an underwritten public offering of...
Vanderbilt wins USD 1.77 million NIH grant to probe TBX4 pulmonary hypertension mechanisms
orglookupsummary note: The verified AllSci organization profile URL from orglookupsummary is...
CervoMed locks in neflamapimod exclusivity through 2042 with pure DLB patent strategy
Boston-based CervoMed Inc. (Nasdaq: CRVO) received a notice of allowance from the USPTO for a method-of-treatment patent protecting the use of neflamapimod…
Immunomic launches first self-amplifying RNA vaccine trial in triple-negative breast cancer
Privately held Rockville, Maryland-based Immunomic Therapeutics, Inc. has initiated a first-in-human Phase I trial of ITI-5000, a self-amplifying RNA...
Curium clears patent hurdle to challenge Novartis’s lutetium Lu 177 dotatate monopoly
Boston-based Curium Pharma prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications (AAA) before the Delaware US District Court,…
NYU investigates long non-coding RNAs as drivers of stress susceptibility and resilience
New York University School of Medicine has received a USD 1.69 million NIH R56 award to investigate the role of long non-coding RNAs in stress...
Jinan University develops light-activated hydrogel system targeting lipid metabolism and postsurgical tumor recurrence
Researchers at Jinan University in Guangzhou, China have reported a thermotropic hydrogel tumor therapy platform that exploits the fatty acid-rich...
Teva files Emalex's ecopipam with US FDA for first approval as Tourette's therapy
Teva Pharmaceutical Industries (NYSE: TEVA) has submitted a New Drug Application (NDA) to the US FDA for ecopipam, an investigational selective dopamine D1...
Scripps wins NCI renewal to study circadian control of HIF2α in kidney cancer
Scripps Research has received a USD 1.39 million NCI R01 renewal to investigate how circadian clock proteins regulate HIF2α activity in clear cell renal...
Mabwell's Nectin-4 ADC challenges Pfizer's Tivdak with 77% response rate in combination study
China-based Mabwell (688062.SH, 02493.HK) reported early-stage clinical data for its Nectin-4-targeting antibody-drug conjugate 9MW2821 (bulumtatug...
UBC researchers suggest semaglutide's skeletal effects reflect weight loss, not GLP-1 activity
Researchers at the University of British Columbia (UBC) in Vancouver, Canada report that semaglutide produces measurable reductions in bone mass and...
Novocure's glioblastoma expansion bid fails, leaving Optune's label unchanged
A Phase III trial failure that leaves Novocure's approved label intact but closes the door on a meaningful expansion opportunity — that is the central...
The AllSci Brief
Systematic R&D and deal news. Daily.